CRP and colorectal carcinoma: The pooled results demonstrated a statistically significant reduction in CRP levels among CRC patients receiving ω-3 PUFA supplementation compared to placebo controls [MD = −16.90, 95% CI (−28.36, −5.43), Z = 2.89, p = 0.004 < 0.05].